Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 3:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 232 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Duchenne Disease Clear all
Completed Phase 2 Interventional Results available

Twice Weekly Steroids and Exercise as Therapy for DMD

NCT04322357
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
Prednisone, Exercise Training on standard steroid regimen, Exercise training on twice-weekly steroids
Drug · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 9 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 1, 2026, 3:15 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Pediatric Radio Frequency Coils Generic

NCT01633866
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Musculoskeletal Abnormalities
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2031
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 1, 2026, 3:15 PM EDT
Terminated Phase 1 Interventional

A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74

NCT06597656
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
delandistrogene moxeparvovec, Plasmapheresis
Genetic · Procedure
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years to 8 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Gainesville, Florida • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 1, 2026, 3:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

NCT03648827
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
2 Years to 7 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 1, 2026, 3:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy

NCT03039686
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
RO7239361, Placebo for RO7239361
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
6 Years to 11 Years · Male only
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Palo Alto, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 1, 2026, 3:15 PM EDT
Completed No phase listed Observational

CureDuchenne Link®: A Resource for Research

NCT04972604
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Interventions
Not listed
Lead sponsor
CureDuchenne
Other
Eligibility
4 Weeks and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Newport Beach, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 1, 2026, 3:15 PM EDT
Completed Phase 2 Interventional

KUL0401: An Open-label Pilot Study of Oxatomide in Steroid-Naive Duchenne Muscular Dystrophy

NCT00033813
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Oxatomide (tinset)
Drug
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
5 Years to 10 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Sep 1, 2026, 3:15 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

NCT05524883
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
DYNE-251, Placebo
Drug
Lead sponsor
Dyne Therapeutics
Industry
Eligibility
4 Years to 16 Years · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 1, 2026, 3:15 PM EDT
Recruiting No phase listed Observational

A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy

NCT07127978
View directory record Official record
Conditions
Duchene Muscular Dystrophy
Interventions
Not listed
Lead sponsor
ITF Therapeutics LLC
Industry
Eligibility
6 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
9
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 1, 2026, 3:15 PM EDT
Terminated Phase 2 Interventional

Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

NCT05429372
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
PF-06939926
Genetic
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 3 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Gainesville, Florida • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 1, 2026, 3:15 PM EDT
Completed Phase 2Phase 3 Interventional

Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies

NCT01126697
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb Girdle Muscular Dystrophy
Interventions
Coenzyme Q10 and Lisinopril
Drug
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
8 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 1, 2026, 3:15 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

NCT03703882
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Edasalonexent, Placebo
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
4 Years to 7 Years · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 1, 2026, 3:15 PM EDT
Not listed Not applicable Interventional

Schulze Muscular Dystrophy Ability Clinical Study

NCT05409079
View directory record Official record
Conditions
Muscular Dystrophies, Spinal Muscular Atrophy, Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy, FSHD, Cerebral Palsy, Becker Muscular Dystrophy
Interventions
Abilitech Assist
Device
Lead sponsor
AbiliTech Medical Inc.
Industry
Eligibility
10 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Sep 1, 2026, 3:15 PM EDT
Recruiting No phase listed Observational

Molecular Analysis of Patients With Neuromuscular Disease

NCT00390104
View directory record Official record
Conditions
Neuromuscular; Disorder, Hereditary, Duchenne/Becker Muscular Dystrophy, Limb-girdle Muscular Dystrophy
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Week to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 1, 2026, 3:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Magnetic Resonance and Optical Imaging of Dystrophic and Damaged Muscle

NCT02168114
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Exercising, Optical and Magnetic Resonance Imaging and Spectroscopy
Other · Procedure
Lead sponsor
University of Florida
Other
Eligibility
10 Years to 55 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 1, 2026, 3:15 PM EDT
Completed Phase 2 Interventional Results available

A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.

NCT04179409
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Amondys 45, Exondys 51, Vyondys 53
Drug
Lead sponsor
Kevin Flanigan
Other
Eligibility
6 Months and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 1, 2026, 3:15 PM EDT
Completed No phase listed Observational

Assessment of Cardiopulmonary Function in Duchenne Muscular Dystrophy

NCT02195999
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Magnetic Resonance Imaging (MRI), Pulmonary Function Testing (PFT), Metabolic Exercise Testing using stationary bicycle, Echocardiogram
Other
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 15 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 7, 2019 · Synced Sep 1, 2026, 3:15 PM EDT
Completed Phase 2 Interventional

An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy

NCT00033189
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Coenzyme Q10
Drug
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
5 Years to 11 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Washington D.C., District of Columbia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 15, 2010 · Synced Sep 1, 2026, 3:15 PM EDT
Completed Phase 1 Interventional

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects

NCT01128855
View directory record Official record
Conditions
Muscular Dystrophies
Interventions
3 mg/kg GSK2402968, 6 mg/kg GSK2402968, 9 mg/kg GSK2402968, 12 mg/kg GSK2402968, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 1, 2026, 3:15 PM EDT
Terminated Phase 3 Interventional Results available

An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy

NCT02090959
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
7 Years to 15 Years · Male only
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
21
States / cities
Los Angeles, California • Sacramento, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 1, 2026, 3:15 PM EDT
Recruiting Phase 2Phase 3 Interventional

Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

NCT03373968
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Givinostat
Drug
Lead sponsor
Italfarmaco
Industry
Eligibility
7 Years and older · Male only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
10
States / cities
Sacramento, California • San Diego, California • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 1, 2026, 3:15 PM EDT
Active, not recruiting Phase 2 Interventional

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping

NCT06244082
View directory record Official record
Conditions
DMD, Duchenne Muscular Dystrophy, Duchenne, Exon 44
Interventions
AOC 1044
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
7 Years to 27 Years · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Little Rock, Arkansas • La Jolla, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 1, 2026, 3:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Wearable Technology to Assess Gait Function in SMA and DMD

NCT04193085
View directory record Official record
Conditions
Spinal Muscular Atrophy Type 3, Duchenne Muscular Dystrophy
Interventions
Observational
Other
Lead sponsor
Columbia University
Other
Eligibility
5 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Sep 1, 2026, 3:15 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Wearable Technology to Evaluate Hyperglycemia and HRV in DMD

NCT06124196
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
wearable technology
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
10 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 1, 2026, 3:15 PM EDT